Antiplatelet activities of anthrax lethal toxin are associated with suppressed p42/44 and p38 mitogen-activated protein kinase pathways in the platelets

Journal of Infectious Diseases

Volumn 192, Issue 8, 2005, Pages 1465-1474

  Kau, Jyh Hwa ^a   Sun, Der Shan ^c   Tsai, Wei Jern ^b   Shyu, Huey Fen ^a   Huang, Hsin Hsien ^a   Lin, Hung Chi ^a   Chang, Hsin Hou ^c  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b National Research Institute of Chinese Medicine   (Taiwan)

^c TZU CHI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTHRAX TOXIN; ARGINYLGLYCYLASPARTIC ACID; DISINTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PADGEM PROTEIN; RHODOSTOMIN; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACILLUS ANTHRACIS; BLEEDING; BLOOD SAMPLING; CELL INTERACTION; CONTROLLED STUDY; DISEASE SEVERITY; ENDOTHELIUM CELL; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REPRESSION; EXPERIMENTAL MODEL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MORTALITY; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYMPTOM; TARGET CELL; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION INHIBITION; WESTERN BLOTTING;

ANIMALS; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; BLOOD PLATELETS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; P38 MITOGEN-ACTIVATED PROTEIN KINASES; VIRULENCE;

EID: 25844500354     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/491477     Document Type: Article

References (54)

1. Beall FA, Taylor MJ, Thorne CB. Rapid lethal effect in rats of a third component found upon fractionating the toxin of Bacillus anthracis. J Bacteriol 1962; 83:1274-80.
2. Cataldi A, Labruyere E, Mock M. Construction and characterization of a protective antigen-deficient Bacillus anthracis strain. Mol Microbiol 1990; 4:1111-7.
3. Leppla SA. The bifactorial Bacillus anthracis lethal and oedema toxins. In: Alouf JE, Freer JH, eds. The comprehensive sourcebook of bacterial protein toxins. 2nd edition. New York: Academic Press, 1991:243-63.
4. Gordon VM, Leppla SH, Hewlett EL. Inhibitors of receptor-mediated endocytosis block the entry of Bacillus anthracis adenylate cyclase toxin but not that of Bordetella pertussis adenylate cyclase toxin. Infect Immun 1988; 56:1066-9.
5. Duesbery NS, Webb CP, Leppla SH, et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998; 280:734-7.
6. Hanna PC, Acosta D, Collier RJ. On the role of macrophages in anthrax. Proc Natl Acad Sci USA 1993; 90:10198-201.
7. Kau JH, Lin CG, Huang HH, et al. Calyculin A sensitive protein phosphatase is required for Bacillus anthracis lethal toxin induced cytotoxicity. Curr Microbiol 2002; 44:106-11.
8. Park JM, Greten FR, Li ZW, Karin M. Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science 2002; 297: 2048-51.
9. Artenstein AW, Opal SM, Cristofaro P, et al. Chloroquine enhances survival in Bacillus anthracis intoxication. J Infect Dis 2004; 190:1655-60.
10. Dixon TC, Meselson M, Guillemin J, Hanna PC. Anthrax. N Engl J Med 1999; 341:815-26.
11. Wu AG, Alibek D, Li YL, Bradburne C, Bailey CL, Alibek K. Anthrax toxin induces hemolysis: an indirect effect through polymorphonuclear cells. J Infect Dis 2003; 188:1138-41.
12. Moayeri M, Haines D, Young HA, Leppla SH. Bacillus anthracis lethal toxin induces TNF-α-independent hypoxia-mediated toxicity in mice. J Clin Invest 2003; 112:670-82.
13. Moayeri M, Leppla SH. The roles of anthrax toxin in pathogenesis. Curr Opin Microbiol 2004; 7:19-24.
14. Hedlund KW In: Hardegree MC, Tu AT, eds. Handbook of natural toxins. Vol. 4. New York: Dekker, 1988:371-81.
15. Fritz DL, Jaax NK, Lawrence WB, et al. Pathology of experimental inhalation anthrax in the rhesus monkey. Lab Invest 1995; 73:691-702.
16. Vasconcelos D, Barnewall R, Babin M, et al. Pathology of inhalation anthrax in cynomolgus monkeys (Macaca fascicularis). Lab Invest 2003; 83:1201-9.
17. Suffin SC, Carnes WH, Kaufmann AF. Inhalation anthrax in a home craftsman. Hum Pathol 1978; 9:594-7.
18. Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci USA 1993; 90:2291-4.
19. Shafazand S, Doyle R, Ruoss S, Weinacker A, Raffin TA. Inhalational anthrax: epidemiology, diagnosis, and management. Chest 1999; 116: 1369-76.
20. Shieh WJ, Guarner J, Paddock C, et al. The critical role of pathology in the investigation of bioterrorism-related cutaneous anthrax. Am J Pathol 2003; 163:1901-10.
21. Barakat LA, Quentzel HL, Jernigan JA, et al. Fatal inhalational anthrax in a 94-year-old Connecticut woman. JAMA 2002; 287:863-8.
22. Borsch-Haubold AG, Kramer RM, Watson SP. Inhibition of mitogen-activated protein kinase kinase does not impair primary activation of human platelets. Biochem J 1996; 318:207-12.
23. Borsch-Haubold AG, Pasquet S, Watson SP. Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059: SB 203580 also inhibits thromboxane synthase. J Biol Chem 1998; 273:28766-72.
24. 3. J Biol Chem 2001; 276:42226-32.
25. Lin CG, Kao YT, Liu WT, et al. Cytotoxic effects of anthrax lethal toxin on macrophage-like cell line J774A.1. Curr Microbiol 1996; 33: 224-7.
26. Witschi H, Espiritu I, Uyeminami D. Chemoprevention of tobacco smoke-induced lung tumors in A/J strain mice with dietary myo-inositol and dexamethasone. Carcinogenesis 1999; 20:1375-8.
27. Chang HH, Tsai WJ, Lo SJ. Glutathione S-transferase-rhodostomin fusion protein inhibits platelet aggregation and induces platelet shape change. Toxicon 1997; 35:195-204.
28. Chang HH, Lin CH, Lo SJ. Recombinant rhodostomin substrates induce transformation and active calcium oscillation in human platelets. Exp Cell Res 1999; 250:387-400.
29. Andre P, Hartwell D, Hrachovinova I, Saffaripour S, Wagner DD. Procoagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci USA 2000; 97:13835-40.
30. Carey MJ, Rodgers GM. Disseminated intravascular coagulation: clinical and laboratory aspects. Am J Hematol 1998; 59:65-73.
31. + exchanger. J Biomed Sci 2004; 11:19-26.
32. Hsiao G, Shen MY, Fang CL, et al. Morphine-potentiated platelet aggregation in in vitro and platelet plug formation in in vivo experiments. J Biomed Sci 2003; 10:292-301.
33. Tseng YL, Peng HC, Huang TF. Rhodostomin, a disintegrin, inhibits adhesion of neutrophils to fibrinogen and attenuates superoxide production. J Biomed Sci 2004; 11:683-91.
34. Heilmann C, Niemann S, Sinha B, Herrmann M, Kehrel BE, Peters G. Staphylococcus aureus fibronectin-binding protein (FnBP)-mediated adherence to platelets, and aggregation of platelets induced by FnBPA but not by FnBPB. J Infect Dis 2004; 190:321-9.
35. +-treated primary cortical neurons. Cell Biol Int 2003; 27:769-77.
36. Chang H, Shvu KG, Lin S, et al. The plasminogen activator inhibitor-1 gene is induced by cell adhesion through the MEK/ERK pathway. J Biomed Sci 2003; 10:738-45.
37. Lin CC, Sun CC, Luo SF, et al. Induction of cyclooxygenase-2 expression in human tracheal smooth muscle cells by interleukin-1β: involvement of p42/p44 and p38 mitogen-activated protein kinases and nuclear factor-κB. J Biomed Sci 2004; 11:377-90.
38. Yang CM, Chien CS, Ma YH, Hsiao LD, Lin CH, Wu C. Bradykinin B2 receptor-mediated proliferation via activation of the Ras/Raf/MEK/MAPK pathway in rat vascular smooth muscle cells. J Biomed Sci 2003; 10:208-18.
39. Chen HC, Lin HC, Liu CY, et al. Neutrophil elastase induces IL-8 synthesis by lung epithelial cells via the mitogen-activated protein kinase pathway. J Biomed Sci 2004; 11:49-58.
40. Chang HH, Lo SJ. Full-spreading platelets induced by the recombinant rhodostomin are via binding to integrins and correlated with FAK phosphorylation. Toxicon 1998; 36:1087-99.
41. 51 sequence of rhodostomin in binding to integrin αIIbβ3. Biochem J 2001; 357:57-64.
42. Rasheed H, Saeed SA. Involvement of thromboxane A2 and tyrosine kinase in the synergistic interaction of platelet activating factor and calcium ionophore A23187 in human platelet aggregation. Exp Mol Med 2004; 36:220-5.
43. Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 2002; 300:729-35.
44. Zaucha GM, Pitt LM, Estep J, Ivins BE, Friedlander AM. The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch Pathol Lab Med 1998; 122:982-92.
45. Kirby JE. Anthrax lethal toxin induces human endothelial cell apoptosis. Infect Immun 2004; 72:430-9.
46. Merten M, Chow T, Hellums JD, Thiagarajan P. A new role for P-selectin in shear-induced platelet aggregation. Circulation 2000; 102: 2045-50.
47. Merten M, Thiagarajan P. P-selectin expression on platelets determines size and stability of platelet aggregates. Circulation 2000; 102:1931-6.
48. Frenette PS, Denis CV, Weiss L, et al. P-selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J Exp Med 2000; 191:1413-22.
49. Padilla A, Moake JL, Bernardo A, et al. P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface. Blood 2004; 103:2150-6.
50. Agrawal A, Lingappa J, Leppla SH, et al. Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. Nature 2003; 424:329-34.
51. Prince AS. The host response to anthrax lethal toxin: unexpected observations. J Clin Invest 2003; 112:656-8.
52. Kakkar AK, Lefer DJ. Leukocyte and endothelial adhesion molecule studies in knockout mice. Curr Opin Pharmacol 2004; 4:154-8.
53. Ley K. The role of selectins in inflammation and disease. Trends Mol Med 2003; 9:263-8.
54. Theoret JF, Bienvenu JG, Kumar A, Merhi Y. P-selectin antagonism with recombinant p-selectin glycoprotein ligand-1 (rPSGL-Ig) inhibits circulating activated platelet binding to neutrophils induced by damaged arterial surfaces. J Pharmacol Exp Ther 2001; 298:658-64.